DNMT3B Antibody

Western Blot: DNMT3B Antibody [NB300-516]

Western Blot: DNMT3B Antibody [NB300-516] - Western blot analysis of DNMT3B level in wildtype DOK cells (Wt), Are-L and NNK-L DOK cells after treatment with 5-aza-dC (5uM) for 5 days. a-tubulin was used as internal control. Image collected and cropped by CiteAb from the following publication (jbiomedsci.biomedcentral.com/articles/10.1186/s12929-020-00644-z), licensed under a CC-BY license.

Immunohistochemistry-Paraffin: DNMT3B Antibody [NB300-516]

Immunohistochemistry-Paraffin: DNMT3B Antibody [NB300-516] - Analysis showing positive staining in the nucleus of Human testis tissue (right) compared with a negative control in the absence of primary antibody (left).

Immunohistochemistry-Paraffin: DNMT3B Antibody [NB300-516]

Immunohistochemistry-Paraffin: DNMT3B Antibody [NB300-516] - Analysis showing positive staining in the nucleus and cytoplasm of Mouse brain tissue (right) compared with a negative control in the absence of primary antibody (left).

Simple Western: DNMT3B Antibody [NB300-516]

Simple Western: DNMT3B Antibody [NB300-516] - Simple Western lane view shows a specific band for DNMT3B in 0.5 mg/mL of BG01V lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. * Non-specific interaction with the 230 kDa Simple Western standard may be seen with this antibody

Simple Western: DNMT3B Antibody [NB300-516]

Simple Western: DNMT3B Antibody [NB300-516] - Analysis of 25 ug of HeLa cell lysates and a molecular weight protein ladder.

Knockdown Validated: DNMT3B Antibody [NB300-516]

Knockdown Validated: DNMT3B Antibody [NB300-516] - RT-PCR and Western blot analysis of DNMT3B in SCC-15 and OEC-M1 cells following DNMT3B knockdown (si-DNMT3B) or non-targeting siRNA control (si-SC) for 48h. GAPDH and a-tubulin were used as internal control, respectively. Image collected and cropped by CiteAb from the following publication (jbiomedsci.biomedcentral.com/articles/10.1186/s12929-020-00644-z), licensed under a CC-BY license.

Chromatin Immunoprecipitation: DNMT3B Antibody [NB300-516] -

Epigenetic changes & protein binding at Ankrd26 promoter in eAT from mice upon 22 weeks of HFD.ChIP of DNMT1, DNMT3a, DNMT3b (a) & MBD2 (b) binding at Ankrd26 promoter region (−553 bp/−348 bp). (c) MNase for Nuc-2 (−257 bp/−198 bp) & Nuc-1 (−84 bp/−25 bp) occupancy at Ankrd26 promoter. (d) ChIP for acetyl-H4 enrichment at Nuc-2 & Nuc-1. (e) ChIP of RNA Pol II binding at Ankrd26 TSS (+16 bp/+159 bp). (a,b) & (d,e), ChIP enrichment is relative to Input chromatin. (a–e), results are mean ± SD from three independent experiments. **p < 0.01 & ***p < 0.001 vs STD. Image collected & cropped by CiteAb from the following publication (https://www.nature.com/articles/srep43526), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: DNMT3B Antibody [NB300-516] -

Western Blot: DNMT3B Antibody [NB300-516] - DNMT3B is a direct target of miR-30a & miR-379. a The effect of miRNA mimics (PM-30a or PM-379, 20 nM) on the luciferase activities of the constructs containing the wild-type (wt-3′-UTR) or mutant-type 3′-UTR (mt-30a-3′-UTR or mt-379-3′-UTR) in OEC-M1 cells. The relative luciferase activity of each sample is measured at 48 h after transfection & normalized to Renilla luciferase activity. The data are represented as mean ± SD; ***p < 0.001 versus control mimics (PM-NC). b RT-PCR & Western blot analysis of DNMT3B level in SCC-15 & OEC-M1 cells after treatment with control mimics (NC), or miRNA mimics (PM-30a or PM-379, 20 nM) or miRNA inhibitor (AM-30a or AM-379, 20 nM) for 48 h. GAPDH & alpha-tubulin were used as internal control, respectively. c RT-PCR analysis of ADHFE1 & ALDH1A2 expression level after treatment with control mimics (NC, 20 nM), or miRNA mimics (PM-30a or PM-379, 20 nM) for 48 h in SCC-15 & OEC-M1 cells. GAPDH was used as internal control. d Relative miR-30a & miR-379 expression levels in 33 of adjacent normal tissues (N) compared with their own tumors (T). e Correlation analysis of DNMT3B & miR-30a or miR-379 in OSCC patients (n = 33) by qRT-PCR analysis. Pearson correlation coefficients & p-values were calculated as indicated. Red, tumor part; green, normal part Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32238162), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: DNMT3B Antibody [NB300-516] -

Western Blot: DNMT3B Antibody [NB300-516] - Arecoline & NNK induced DNMT3B activity & repressed ADHFE1, ALDH1A2 & miRNAs expression. a qRT–PCR analysis of miR-30a & miR-379 expression level after treatment with arecoline (50 μM) or NNK (10 μM) for indicated days. b RT-PCR analysis of ADHFE1, ALDH1A2 level & western blot analysis of DNMT3B level in DOK cells after treatment with arecoline (50 μM) or NNK (10 μM) for indicated times. GAPDH & alpha-tubulin were used as internal control. c ChIP assay of ADHFE1 & ALDH1A2 promoter region was performed with DOK cells using anti-DNMT3B antibody after treatment with vehicle control (DMSO, 10 nM), arecoline (50 μM) or NNK (10 μM) for 5 days. Mouse IgG (mIgG) antibody was used as negative control. d RT-PCR analysis of ADHFE1 & ALDH1A2 level in DOK cells after treatment with arecoline (50 μM) or NNK (10 μM) alone or combined with 5-aza-dC (5 μM) for 5 days. GAPDH was used as internal control. e qRT-PCR analysis of ADHFE1 & ALDH1A2 level in DOK cells after treatment with vehicle control (C), or arecoline (50 μM) plus control mimics (NC), miR-30a (20 nM), miR-379 (20 nM), or NNK (10 μM) plus control mimics (NC), miR-30a (20 nM), miR-379 (20 nM) for 5 days. GAPDH was used as an internal control. All data are presented as mean ± SD; **p < 0.01; ***p < 0.001 Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32238162), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: DNMT3B Antibody [NB300-516] -

Western Blot: DNMT3B Antibody [NB300-516] - Arecoline & NNK induced DNMT3B activity & repressed ADHFE1, ALDH1A2 & miRNAs expression. a qRT–PCR analysis of miR-30a & miR-379 expression level after treatment with arecoline (50 μM) or NNK (10 μM) for indicated days. b RT-PCR analysis of ADHFE1, ALDH1A2 level & western blot analysis of DNMT3B level in DOK cells after treatment with arecoline (50 μM) or NNK (10 μM) for indicated times. GAPDH & alpha-tubulin were used as internal control. c ChIP assay of ADHFE1 & ALDH1A2 promoter region was performed with DOK cells using anti-DNMT3B antibody after treatment with vehicle control (DMSO, 10 nM), arecoline (50 μM) or NNK (10 μM) for 5 days. Mouse IgG (mIgG) antibody was used as negative control. d RT-PCR analysis of ADHFE1 & ALDH1A2 level in DOK cells after treatment with arecoline (50 μM) or NNK (10 μM) alone or combined with 5-aza-dC (5 μM) for 5 days. GAPDH was used as internal control. e qRT-PCR analysis of ADHFE1 & ALDH1A2 level in DOK cells after treatment with vehicle control (C), or arecoline (50 μM) plus control mimics (NC), miR-30a (20 nM), miR-379 (20 nM), or NNK (10 μM) plus control mimics (NC), miR-30a (20 nM), miR-379 (20 nM) for 5 days. GAPDH was used as an internal control. All data are presented as mean ± SD; **p < 0.01; ***p < 0.001 Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32238162), licensed under a CC-BY license. Not internally tested by Novus Biologicals.